TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma
October 26, 2022 07:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...
TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology
October 13, 2022 07:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced...
TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference
September 27, 2022 08:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced...
TransCode Therapeutics Appoints MicroRNA Pioneer, Dr. Frank Slack, to its Advisory Board
September 08, 2022 08:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced...
TransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business Update
August 15, 2022 16:15 ET
|
TransCode Therapeutics, Inc.
BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...
TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology
August 02, 2022 07:00 ET
|
TransCode Therapeutics, Inc.
BOSTON and HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA oncology company, and The University of Texas MD Anderson...
TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio
July 11, 2022 16:05 ET
|
TransCode Therapeutics, Inc.
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced extension of its...
TransCode Therapeutics to Participate at BIO International Convention
June 09, 2022 09:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, June 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the BIO International Convention to be held June...
TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award
June 01, 2022 09:00 ET
|
TransCode Therapeutics, Inc.
Funding is part of a 2021 Fast-Track Small Business Innovation Research (SBIR) grant to Support Clinical Development of First-in-Class Therapy for Advanced Solid Tumors First SBIR program...
TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference
May 20, 2022 09:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The in-person...